SCHEMBL3364540

SCHEMBL3364540

CCOC(=O)Cc1cccc(Br)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
CYP1A2 P05177 1/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 1/20 0.45
THRB P10828 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HSD17B10 Q99714 1/20 0.44
CHEK1 O14757 1/20 0.44
LMNA P02545 3/20 0.43
TSHR P16473 1/20 0.43
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29502494 1.00 KMT2A (0.46) KMT2AMEN1CYP1A2ALDH1A1KDM4E
SCHEMBL14732977 0.91 KMT2A (0.44) KMT2AMEN1CYP1A2ALDH1A1KDM4E
SCHEMBL1511343 0.84 CYP4F2 (0.48) KMT2AMEN1CYP1A2ALDH1A1KDM4E
SCHEMBL15709960 0.83 ALDH1A1 (0.41) KMT2AALDH1A1KDM4EMAPTMAPK1
SCHEMBL30106103 0.83 ALDH1A1 (0.41) KMT2AALDH1A1KDM4EMAPTMAPK1
SCHEMBL1135252 0.83 ALDH1A1 (0.48) KMT2AMEN1CYP1A2ALDH1A1KDM4E
SCHEMBL931693 0.83 MAPK1 (0.46) KMT2AMEN1CYP1A2ALDH1A1MAPT
SCHEMBL22070548 0.82 KMT2A (0.47) KMT2AMEN1CYP1A2ALDH1A1MAPT
SCHEMBL14677477 0.82 KMT2A (0.47) KMT2AMEN1CYP1A2ALDH1A1KDM4E
SCHEMBL13117164 0.82 POLB (0.47) KMT2AMEN1CYP1A2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023131951-A1 NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES FORTEPHEST LTD. (IL) 2023-07-13 WO claimed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 US disclosed
US-20260034111-A1 NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2026-02-05 US disclosed
US-20250282756-A1 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors STEP PHARMA S.A.S. (FR) 2025-09-11 US disclosed
US-12371419-B2 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors STEP PHARMA S.A.S. (FR) 2025-07-29 US disclosed
EP-4561991-A1 NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS Cayman Chemical Company, Inc. (US) 2025-06-04 EP disclosed
EP-4562015-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
US-20250066324-A1 AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2025-02-27 US disclosed
US-20240284907-A1 NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES FORTEPHEST LTD. (IL) 2024-08-29 US disclosed
US-11987573-B2 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors STEP PHARMA S.A.S. (FR) 2024-05-21 US disclosed
US-20120184539-A1 Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-07-19 US disclosed
WO-2012095469-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2012-07-19 WO disclosed
WO-2011159760-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE VITAE PHARMACEUTICALS, INC. (US) 2011-12-22 WO disclosed
WO-2011159760-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE VITAE PHARMACEUTICALS, INC. (US) 2011-12-22 WO disclosed
US-20110312974-A1 HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-12-22 US disclosed
US-20110312974-A1 HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-12-22 US disclosed
US-20110312974-A1 HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-12-22 US disclosed
WO-2010037059-A2 HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-04-01 WO disclosed
WO-2010037059-A2 HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-04-01 WO disclosed
CN-101432284-A Dihydropyrazolopyrimidinone derivative BANYU PHARMA CO LTD (JP) 2009-05-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371419-B2 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors CTPS1, CTPS2, TYMS KMT2A 3698/4885MEN1 4378/4885CYP1A2 758/4885
US-20260034111-A1 NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS PLA2G2F, PLA2R1, PLA2G12A KMT2A 3371/4885MEN1 3794/4885CYP1A2 1230/4885
US-20110312974-A1 HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 KMT2A 4142/4885MEN1 4828/4885CYP1A2 241/4885
US-20250282756-A1 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors CTPS1, CTPS2, TYMS KMT2A 3679/4885MEN1 4385/4885CYP1A2 796/4885
US-20250066324-A1 AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS KMT2A 3698/4885MEN1 4378/4885CYP1A2 758/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 KMT2A 605/4885MEN1 4755/4885CYP1A2 2456/4885
US-11987573-B2 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors CTPS1, CTPS2, TYMS KMT2A 3698/4885MEN1 4378/4885CYP1A2 758/4885
US-20240284907-A1 NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES DDT, DDC, GLUL KMT2A 291/4885MEN1 4773/4885CYP1A2 1222/4885
US-20120184539-A1 Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders BACE2, BACE1, PSEN2 KMT2A 2375/4885MEN1 2724/4885CYP1A2 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.